Table 1 Demographic data

From: Low-dose add-on memantine treatment may improve cognitive performance and self-reported health conditions in opioid-dependent patients undergoing methadone-maintenance-therapy

  

Heroin-Dependent Patients

 
 

HC (n = 37)

MMT+P (n = 42)

MMT+M (n = 39)

χ2/F (p)

Gender (F/M)

31/6

36/6

34/5

0.18 (0.92)

Age (years)

36.35 ± 6.73

37.71 ± 6.57

36.24 ± 7.48

0.57 (0.57)

Duration of heroin use (years)

--

7.15 ± 6.07

7.95 ± 7.01

0.29 (0.59)

 Mean methadone dose (mg/kg ± SD)

--

35.37 ± 20.04

39.73 ± 21.31

−0.93 (0.35)

  

(SE = 3.13)

(SE = 3.50)

 

Other substance use

    

 Amphetamine (numbers)

--

40/49

39/39

0.09 (0.77)

 Duration of amphetamine use (years)

--

3.80 ± 4.56

3.69 ± 5.82

0.09 (0.93)

 Alcohol (numbers)

--

11/42

12/39

0.21 (0.65)

Urine test

    

 Amphetamine (+/−)

--

9/33

2/37

4.58 (0.03)

 Morphine (+/−)

--

24/17

22/14

0.05 (0.82)

  1. MMT+P, methadone maintenance therapy plus placebo; MMT+M, methadone maintenance therapy plus memantine; SD, standard deviation; SE standard error.